Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis
Case Reports in Endocrinology · 2015 · 2015 · 1-4
DOI: 10.1155/2015/917869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Endocrinology, 2015. Verfasst von Natalia M Branis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, P.O. Box 693, Roche…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Obesity is common in patients with type 1 and type 2 diabetes. Amphetamine-like analogues comprise the most popular class of weight loss medications. We present a case of a 34-year-old African American female with a history of type 1 diabetes, dyslipidemia, and obesity who developed diabetic ketoacidosis (DKA) after starting Diethylpropion for the purpose of weight loss. Shortly after starting Diethylpropion, she developed nausea, vomiting, and periumbilical pain. Blood work revealed glucose of 718 mg/dL, pH 7.32 (7.35–7.45), bicarbonate 16 mmol/L (22–29 mmol/L), and anion gap 19 mmol/L (8–16 mmol/L). Urine analysis demonstrated large amount of ketones. She was hospitalized and successfully treated for DKA. Diethylpropion was discontinued. Amphetamine-like analogues administration leads to norepinephrine release from the lateral hypothalamus which results in the appetite suppression. Peripheral norepinephrine concentration rises as well. Norepinephrine stimulates adipocyte lipolysis and thereby increases nonesterified fatty acids (NEFA) availability. It promotes β -oxidation of NEFA to ketone bodies while decreasing metabolic clearance rate of ketones. In the setting of acute insulin deficiency these effects are augmented. Females are more sensitive to norepinephrine effects compared to males. In conclusion, amphetamine-like analogues lead to a release of norepinephrine which can result in a clinically significant ketosis, especially in the setting of insulin deficiency.
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, P.O. Box 693, Rochester, NY 14642, USA.
Zitieren
APA
Branis, N. M., & Wittlin, S. D. (2015). Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis. Case Reports in Endocrinology, 2015, 1-4. https://doi.org/10.1155/2015/917869
Vancouver
Branis NM, Wittlin SD. Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis. Case Reports in Endocrinology. 2015;2015:1-4. doi:10.1155/2015/917869
BibTeX
@article{Branis2015,
author = {Branis, Natalia M and Wittlin, Steven D},
title = {Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis},
journal = {Case Reports in Endocrinology},
year = {2015},
volume = {2015},
pages = {1--4},
doi = {10.1155/2015/917869}
}
EUVIMED